MHRA’s Rawlins Says New Approach Needed For Clinical Trials
This article was originally published in The Pink Sheet Daily
The chairman of Britain’s regulator the MHRA says clinical trials need more adaptive designs using smaller patient numbers if drug development costs are to be cut and innovative therapies made more accessible more quickly.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
The submission of more trial data from Roche has prompted the US FDA to extend by three months its decision on whether to approve risdiplam for spinal muscular atrophy.
Experts think GLP-1s in neurodegeneration may be Novo Nordisk’s next opportunity and await readouts from the Phase II ELAD trial in Alzheimer's disease for signals.